DB:7DC

Stock Analysis Report

Executive Summary

Diaceutics Plc provides data analytics and implementation services for pharmaceutical companies worldwide.


Snowflake Analysis

Reasonable growth potential with adequate balance sheet.

Share Price & News

How has Diaceutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 7DC's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

4.8%

7DC

3.3%

DE Life Sciences

9.1%

DE Market


1 Year Return

43.3%

7DC

29.7%

DE Life Sciences

-13.1%

DE Market

Return vs Industry: 7DC exceeded the German Life Sciences industry which returned 29.7% over the past year.

Return vs Market: 7DC exceeded the German Market which returned -13.1% over the past year.


Shareholder returns

7DCIndustryMarket
7 Day4.8%3.3%9.1%
30 Day-1.9%9.8%-1.0%
90 Day28.3%7.9%-20.7%
1 Year43.3%43.3%30.9%29.7%-10.6%-13.1%
3 Yearn/a92.5%82.6%-10.7%-18.1%
5 Yearn/a203.7%183.4%-10.7%-22.8%

Price Volatility Vs. Market

How volatile is Diaceutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Diaceutics undervalued compared to its fair value and its price relative to the market?

221.77x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 7DC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 7DC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 7DC is poor value based on its PE Ratio (221.8x) compared to the Life Sciences industry average (52.8x).

PE vs Market: 7DC is poor value based on its PE Ratio (221.8x) compared to the German market (17.4x).


Price to Earnings Growth Ratio

PEG Ratio: 7DC is poor value based on its PEG Ratio (4.1x)


Price to Book Ratio

PB vs Industry: 7DC is overvalued based on its PB Ratio (4.8x) compared to the XE Life Sciences industry average (3.9x).


Next Steps

Future Growth

How is Diaceutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

54.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 7DC's forecast earnings growth (54.1% per year) is above the savings rate (-0.4%).

Earnings vs Market: 7DC's earnings (54.1% per year) are forecast to grow faster than the German market (14.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 7DC's revenue (18.9% per year) is forecast to grow faster than the German market (3.9% per year).

High Growth Revenue: 7DC's revenue (18.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 7DC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Diaceutics performed over the past 5 years?

0.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 7DC has a high level of non-cash earnings.

Growing Profit Margin: 7DC's current net profit margins (3%) are lower than last year (6.1%).


Past Earnings Growth Analysis

Earnings Trend: 7DC's earnings have grown by 0.2% per year over the past 5 years.

Accelerating Growth: 7DC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 7DC had negative earnings growth (-37.1%) over the past year, making it difficult to compare to the Life Sciences industry average (-1.1%).


Return on Equity

High ROE: 7DC's Return on Equity (2%) is considered low.


Next Steps

Financial Health

How is Diaceutics's financial position?


Financial Position Analysis

Short Term Liabilities: 7DC's short term assets (£18.4M) exceed its short term liabilities (£2.2M).

Long Term Liabilities: 7DC has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 7DC's debt to equity ratio (0.5%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 7DC's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 7DC's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: 7DC's interest payments on its debt are well covered by EBIT (8.5x coverage).


Balance Sheet


Next Steps

Dividend

What is Diaceutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 7DC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 7DC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 7DC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 7DC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 7DC's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average management tenure


CEO

Peter Keeling

no data

Tenure

Mr. Peter Keeling serves as Chief Executive Officer and Director of Diaceutics PLC. Mr. Keeling was Co-founder and Chief Executive at Diagnology Limited. 


Leadership Team

NamePositionTenureCompensationOwnership
Peter Keeling
CEO & Directorno datano data25.19% £27.5m
Philip White
CFO, Company Secretary & Directorno datano data4.35% £4.7m
Damian Thornton
Chief Operating Officerno datano datano data
Jordan Clark
Chief Technical Officerno datano datano data
Zarina Bibi
General Counsel0.92yrno datano data
Ryan Keeling
Chief Innovation Officer & Directorno datano data4.15% £4.5m
Sarah Bondi
Head of Strategic Alliances0.25yrno datano data
Susanne Munksted
Managing Director1.25yrsno datano data
Derek Hosty
Head of Global Data0.67yrno datano data
Amit Jain
Managing Director0.67yrno datano data

0.7yrs

Average Tenure

Experienced Management: 7DC's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 323326.8%.


Top Shareholders

Company Information

Diaceutics PLC's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Diaceutics PLC
  • Ticker: 7DC
  • Exchange: DB
  • Founded:
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£95.677m
  • Listing Market Cap: UK£108.993m
  • Shares outstanding: 69.58m
  • Website: https://www.diaceutics.com

Number of Employees


Location

  • Diaceutics PLC
  • Titanic Suites
  • Enterprise House
  • Belfast
  • County Antrim
  • BT2 8FE
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
7DCDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 2019
DXRXAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPMar 2019

Biography

Diaceutics Plc provides data analytics and implementation services for pharmaceutical companies worldwide. It offers diagnostic landscape services, such as patient journey, lab mapping, diagnostic regulation, turnaround time, and sample availability analysis services; diagnostic tracking services, including lab tracking, patient insights, and physician segmentation services; and diagnostic payers research, diagnostic clinical landscape, integrated mapping research, buying process research, and testers/non-testers research services. The company also provides diagnostic planning services consisting of strategic and technical planning, launch planning, diagnostic partner selection, and financial forecast services; commercialization services comprising content creation, workshops, diagnostic adboards, conference support, and proficiency testing services; and reimbursement services. The company is based in Belfast, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/10 00:04
End of Day Share Price2020/04/09 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.